Brahmi (Bacopa Monnieri Linn) in the treatment of dementia

A pilot study on the effect of Brahmi (Bacopa Monnieri Linn) in various types and grades of dementia by comparing the effect of the drug on the participants using the Global Deterioration Scale

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN18407424

Enrollment

Registered

2016-09-08

Start date

2015-06-01

Completion date

Unknown

Last updated

2016-11-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dementia Mental and Behavioural Disorders Dementia

Interventions

Every patient is administered the extract of Brahmi (Himalaya) in the dose of 250 mg capsules twice daily orally for three months. The GDS was determined before the start of the treatment and again af

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Aged 18 years and over 2. Diagnosis of dementia

Exclusion criteria

Exclusion criteria: 1. History of Intolerance or allergy to Brahmi 2. Type 1 Diabetes Mellitus 3. Pregnancy

Design outcomes

Primary

Measure	Time frame
Alzheimer's progression is measured using the Global Deterioration Scale (GDS) at baseline and 3 months.	—

Secondary

Measure	Time frame
Age-related falls are measured through self-reporting by patients and/or their attendants at baseline, 1 and 3 months.	—

Countries

India

Contacts

Public ContactAjay Kumar Mishra

drakm1969@gmail.com+919431857475

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026